These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 7104195)

  • 1. Tamoxifen, aminoglutethimide and danazol: effect of therapy on hormones in post-menopausal patients with breast cancer.
    Coombes RC; Powles TJ; Rees LH; Ratcliffe WA; Nash AG; Henk M; Ford HT; Gazet JC; Neville AM
    Br J Cancer; 1982 Jul; 46(1):30-4. PubMed ID: 7104195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonism of aminoglutethimide and danazol in the suppression of serum free oestradiol in breast cancer patients.
    Dowsett M; Murray RM; Pitt P; Jeffcoate SL
    Eur J Cancer Clin Oncol; 1985 Sep; 21(9):1063-8. PubMed ID: 4065179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    Br J Cancer; 1984 Sep; 50(3):357-61. PubMed ID: 6540595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of disseminated breast cancer with tamoxifen, aminoglutethimide, hydrocortisone, and danazol, used in combination or sequentially.
    Powles TJ; Ashley S; Ford HT; Gazet JC; Nash AG; Neville AM; Coombes RC
    Lancet; 1984 Jun; 1(8391):1369-73. PubMed ID: 6145832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endocrine treatment of breast cancer: effects upon intratumoral estrone sulfate metabolism and peripheral steroid levels.
    Carlström K; Pousette A; Rannevik G; Sköldefors H; Theve NO; Wilking N
    Breast Cancer Res Treat; 1986; 7 Suppl():S107-9. PubMed ID: 2943337
    [No Abstract]   [Full Text] [Related]  

  • 6. Biochemical basis for the antagonism between aminoglutethimide and danazol in the endocrine treatment of breast cancer.
    Dowsett M; Murray RM; Pitt P; Jeffcoate SL
    Ann Clin Biochem; 1986 May; 23 ( Pt 3)():277-84. PubMed ID: 3789634
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of multiple endocrine therapy for metastatic and locally advanced breast cancer with tamoxifen-aminoglutethimide-danazol compared to tamoxifen used alone.
    Powles TJ; Gordon C; Coombes RC
    Cancer Res; 1982 Aug; 42(8 Suppl):3458s-3460s. PubMed ID: 7044528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of danazol on serum gonadotrophins and steroid hormone concentrations in women with menorrhagia.
    Chimbira TH; Anderson AB; Cope E; Turnbull AC
    Br J Obstet Gynaecol; 1980 Apr; 87(4):330-6. PubMed ID: 7426503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aminoglutethimide dose and hormone suppression in advanced breast cancer.
    Harris AL; Dowsett M; Jeffcoate SL; Smith IE
    Eur J Cancer Clin Oncol; 1983 Apr; 19(4):493-8. PubMed ID: 6222901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine effects of danazol in the treatment of endometriosis.
    Bevan JR; Dowsett M; Jeffcoate SL
    Br J Obstet Gynaecol; 1984 Feb; 91(2):160-6. PubMed ID: 6538094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danazol treatment for advanced breast cancer.
    Coombes RC; Perez D; Gazet JC; Ford HT; Powles TJ
    Cancer Chemother Pharmacol; 1983; 10(3):194-5. PubMed ID: 6345017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of serum prolactin levels in advanced breast cancer.
    Dowsett M; McGarrick GE; Harris AL; Coombes RC; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 Jun; 47(6):763-9. PubMed ID: 6860546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endocrine effects of aminoglutethimide plus hydrocortisone versus effects of high dose of hydrocortisone alone in postmenopausal metastatic breast cancer.
    Alexieva-Figusch J; de Jong FH; Lamberts WJ; van Gilse HA; Klign JG
    Eur J Cancer Clin Oncol; 1987 Sep; 23(9):1349-56. PubMed ID: 2960533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy.
    Dowsett M; Harris AL; Smith IE; Jeffcoate SL
    J Clin Endocrinol Metab; 1984 Jan; 58(1):99-104. PubMed ID: 6227629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aminoglutethimide induced hormone suppression and response to therapy in advanced postmenopausal breast cancer.
    Harris AL; Dowsett M; Smith IE; Jeffcoate S
    Br J Cancer; 1983 Oct; 48(4):585-94. PubMed ID: 6684948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive hormonal therapy in women with advanced breast cancer.
    Ingle JN
    Cancer; 1984 Feb; 53(3 Suppl):766-77. PubMed ID: 6229323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine effects of low dose aminoglutethimide with hydrocortisone--an optimal hormone suppressive regimen.
    Harris AL; Dowsett M; Cantwell BM; Sainsbury JR; Needham G; Farndon J; Wilson R
    Breast Cancer Res Treat; 1986; 7 Suppl():S69-72. PubMed ID: 2943338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of steroid sulfatase activity by danazol.
    Carlström K; Döberl A; Pousette A; Rannevik G; Wilking N
    Acta Obstet Gynecol Scand Suppl; 1984; 123():107-11. PubMed ID: 6238495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of aminoglutethimide in male breast cancer.
    Harris AL; Dowsett M; Stuart-Harris R; Smith IE
    Br J Cancer; 1986 Oct; 54(4):657-60. PubMed ID: 3778807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced breast cancer with aminoglutethimide--response after previous tamoxifen treatment.
    Bezwoda WR; Derman DP; Browde S; Goss G; Lange M
    S Afr Med J; 1984 Sep; 66(10):372-4. PubMed ID: 6484759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.